2Katz DH,Marcelletti JF,Khalil MH,et al.Antiviral activity of 1-do-c osanol,an inhibitor of lipid-enveloped viruses including herpes simplex.Proc Natl Acad Sci USA,1991,88(23):10825-10829.
3Scolaro M J,Gunnill LB,Pope LE,et al.The antiviral drug docosanol as atreatment for Kaposi＇s sarcoma lesions in HIV type 1-infected patients:apilot clinical study.MDS Res Hum Retroviruses,2001.17 (1):35-43.
4Pope LE,Marcelletti JF,Katz LR,et al.The anti-herpes simplex virus ac tivity of n-docosanol includes inhibition of the viral entry process.Antiviral Res,1998,40:85-94.
5Pope LE,Macelletti JF,Katz LR,et al.Anti-herpes simplex virus activity ofn-docosanol correlates with intracellular metabolic conversion of the drug.J Lipid Res,1996,37(10):2167-2178.
6Fuller AO,Spear PG.Anti-glycoprotein D antibodies that permit adsorptionbut block infection by herpes simplex virus I prevent virion-cell fusion atthe cell surface.Proc Natl Acad Sci USA,1987,84(15):5454-5458.
7Montgomery RI,Warner MS,Lum BJ,et al.Herpes simplex virus-I entryZinto cells mediated by a novel member of the TNF/NGF receptor family.Cell,1996,87(3):427-436.
8Roos DS,Choppin PW.Biochemical studies on cell fusion.Ⅱ.Control oflfusion response by lipid alteration.J Cell Biol,1985.101 (4):1591-1598.
9Alrabiah FA,Sacks SL.New antiherpesvirus agents:Their targets and ther-apeutic potential.Drugs,1996,52(1):17-32.
10Habbema L,De Boulle K,Roders GA,et al.n-Docosanol 10% cream in thetreatment of recurrent herpes labialis:a randomised,double-blind,placebo-controlled study.Acta Derm Venereol(Stockh),1996,76(6):479-481.
